Cases were categorized by health status: cases that were otherwise healthy, cases with underlying health conditions that are an indication for seasonal influenza vaccination and cases with underlying health conditions that are not an indication for seasonal influenza vaccination. Health conditions for which vaccine is recommended include chronic heart disease, chronic lung disease (including asthma), diabetes mellitus or other Buparlisib research buy metabolic disorder, cancer, immunodeficiency, immunosuppression, chronic renal disease, anemia, hemoglobinopathy, chronic acetylsalicylic acid therapy, residence in institutional setting,
and health conditions that can compromise respiratory function or increase risk of aspiration . Canadian and American guidelines indicate that these conditions also confer higher risk for adverse outcomes with pandemic H1N1  and . Risk factors, hospital course, outcome and antiviral use were examined for pandemic H1N1 cases. SAS version 9.1.3 (SAS Institute, Cary, NC) was used for all analyses. From May 1, 2009 to August 31, 2009 a total of 324 influenza A cases was reported, as shown in Fig. 1. Pandemic H1N1 Olaparib manufacturer was identified as the subtype in 98.5% of the reported cases; the remainder of the influenza A cases (n = 5) had no subtype information available at the time of our report. The spring wave had a sharp peak with 74.4% of cases occurring
in a 5-week period. Peak hospitalizations occurred during the week of June 13, 2009. Case details were complete for 235 of the 324 cases (73%), with the majority of centers (9/12) having completed Tolmetin detailed reporting on >80% of their cases by August 31, 2009. Details on the 235 completed cases are described below. The last reported case in this series occurred the week of August 17. Fig. 2 shows the age distribution by health status of pandemic cases. The median age of the 235 cases was 4.8 years (range 0–16 years) with 162 children (69%) over the age of 2. Males comprised 55% of cases. Ethnicity data were available on 56% of the cases;
7.2% were First Nations/Aboriginal. In total, 95 (40%) of children were previously healthy. The proportion with at least one underlying health condition increased with age; 33% (24/73) of children under age two had health conditions, compared to 72% (116/162) of children ≥2 years old (Fig. 2). Overall, 121 children (51%) had an underlying health condition for which seasonal influenza vaccine is recommended and of those, 102 were ≥2 years old. Table 1 describes the number and type of underlying conditions. Chronic lung disorders was the largest category (almost 25%) consisting primarily of asthma (n = 37), broncho-pulmonary dysplasia (n = 6) and cerebral palsy with chronic aspiration (n = 5). The majority of children had fever (215, 92%) and cough (213, 91%).